Status:
UNKNOWN
Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Lead Sponsor:
Hamamatsu University
Conditions:
Gastric Cancer
Esophageal Cancer
Eligibility:
All Genders
20-85 years
Phase:
PHASE2
Brief Summary
S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine dehydrogenas...
Eligibility Criteria
Inclusion
- Patients with digestive organ cancer
Exclusion
- Patients without digestive organ cancer
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00197431
Start Date
January 1 2004
Last Update
March 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192